201 related articles for article (PubMed ID: 21059726)
21. Cost-effectiveness analysis of lifestyle interventions for preventing kidney disease in patients with type 2 diabetes.
Suzuki Y; Hoshi K; Shiroiwa T; Fukuda T
Clin Exp Nephrol; 2023 Sep; 27(9):728-736. PubMed ID: 37195388
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of dialysis and kidney transplantation to treat end-stage renal disease in Ukraine.
Hryshchuk SM; Parii VD
Wiad Lek; 2024; 77(4):765-771. PubMed ID: 38865635
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness and cost-utility analysis of type-2 diabetes screening in pharmacies in Iran.
Amirsadri M; Torkpour E
Res Pharm Sci; 2023 Apr; 18(2):210-218. PubMed ID: 36873274
[TBL] [Abstract][Full Text] [Related]
24. Genomic testing for suspected monogenic kidney disease in children and adults: A health economic evaluation.
Wu Y; Jayasinghe K; Stark Z; Quinlan C; Patel C; McCarthy H; Mallawaarachchi AC; Kerr PG; Alexander S; Mallett AJ; Goranitis I;
Genet Med; 2023 Nov; 25(11):100942. PubMed ID: 37489581
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Canakinumab From a Canadian Perspective for Recurrent Cardiovascular Events.
Boczar KE; Beanlands R; Wells G; Coyle D
CJC Open; 2022 May; 4(5):441-448. PubMed ID: 35607490
[TBL] [Abstract][Full Text] [Related]
26. Supportive Care: Economic Considerations in Advanced Kidney Disease.
Morton RL; Kurella Tamura M; Coast J; Davison SN
Clin J Am Soc Nephrol; 2016 Oct; 11(10):1915-1920. PubMed ID: 27510455
[TBL] [Abstract][Full Text] [Related]
27. Nephrology for the people: Presidential Address at the 42nd Regional Meeting of the Japanese Society of Nephrology in Okinawa 2012.
Iseki K
Clin Exp Nephrol; 2013 Aug; 17(4):480-7. PubMed ID: 23392566
[TBL] [Abstract][Full Text] [Related]
28. The effect of model selection on cost-effectiveness research: a comparison of kidney function-based microsimulation and disease grade-based microsimulation in chronic kidney disease modeling.
Hiragi S; Tamura H; Goto R; Kuroda T
BMC Med Inform Decis Mak; 2018 Nov; 18(1):94. PubMed ID: 30413200
[TBL] [Abstract][Full Text] [Related]
29. Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14).
Echeverri J; Martins R; Harenski K; Kampf JP; McPherson P; Textoris J; Koyner JL
Clinicoecon Outcomes Res; 2024; 16():1-12. PubMed ID: 38235419
[TBL] [Abstract][Full Text] [Related]
30. On the rationale of population screening for chronic kidney disease: a public health perspective.
Bochud M
Public Health Rev; 2015; 36():11. PubMed ID: 29450039
[TBL] [Abstract][Full Text] [Related]
31. Screening for chronic kidney disease: where does Europe go?
de Jong PE; van der Velde M; Gansevoort RT; Zoccali C
Clin J Am Soc Nephrol; 2008 Mar; 3(2):616-23. PubMed ID: 18287253
[TBL] [Abstract][Full Text] [Related]
32. A Cost-Effectiveness Model to Determine Ostomy-Related Costs of Care and Health Outcomes Among People With an Ostomy in Canada Using a Ceramide-Infused Skin Barrier.
LeBlanc K; Furtado S; Mings D; Martin M; Evans M; Eaves D; Skountrianos G
J Wound Ostomy Continence Nurs; 2023 Jan-Feb 01; 50(1):31-38. PubMed ID: 36640162
[TBL] [Abstract][Full Text] [Related]
33. Cost Efficacy of Rapid Whole Genome Sequencing in the Pediatric Intensive Care Unit.
Sanford Kobayashi E; Waldman B; Engorn BM; Perofsky K; Allred E; Briggs B; Gatcliffe C; Ramchandar N; Gold JJ; Doshi A; Ingulli EG; Thornburg CD; Benson W; Farnaes L; Chowdhury S; Rego S; Hobbs C; Kingsmore SF; Dimmock DP; Coufal NG
Front Pediatr; 2021; 9():809536. PubMed ID: 35141181
[TBL] [Abstract][Full Text] [Related]
34. Factors Associated with the Development of Chronic Kidney Disease in Patients with Arterial Hypertension.
Goicochea-Rios EDS; Chian-García AM; Yupari-Azabache IL; Gómez Goicochea NI
Int J Nephrol Renovasc Dis; 2024; 17():113-123. PubMed ID: 38566818
[TBL] [Abstract][Full Text] [Related]
35. Kidney disease and care among First Nations people with diabetes in Ontario: a population-based cohort study.
Nash DM; Dirk JS; McArthur E; Green ME; Shah BR; Walker JD; Beaucage M; Jones CR; Garg AX
CMAJ Open; 2019; 7(4):E706-E712. PubMed ID: 31822501
[TBL] [Abstract][Full Text] [Related]
36. eGFR and chronic kidney disease: Time to move forward.
Tomson CR; Lamb EJ; Griffith K; O'Donoghue D; Feehally J
BMJ; 2007 Jul; 335(7611):111. PubMed ID: 17641306
[No Abstract] [Full Text] [Related]
37. Examining chronic kidney disease screening frequency among diabetics: a POMDP approach.
Wu CC; Cao Y; Suen SC; Lin E
Health Care Manag Sci; 2024 Jun; ():. PubMed ID: 38836923
[TBL] [Abstract][Full Text] [Related]
38. A Response to: Letter to the Editor regarding "Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes".
Skolnik N; Style A
Diabetes Ther; 2022 Sep; 13(9):1705-1706. PubMed ID: 35930189
[No Abstract] [Full Text] [Related]
39. Letter to the Editor Regarding "Importance of Early Screening and Diagnosis of Chronic Kidney Disease in Patients with Type 2 Diabetes".
Nataraj M; Maiya AG; Nagaraju SP
Diabetes Ther; 2022 Sep; 13(9):1701-1703. PubMed ID: 35930190
[No Abstract] [Full Text] [Related]
40. Correction to: Lifetime risk of cardiovascular-renal disease in type 2 diabetes: a population-based study in 473,399 individuals.
Zhang R; Mamza JB; Morris T; Godfrey G; Asselbergs FW; Denaxas S; Hemingway H; Banerjee A
BMC Med; 2022 Mar; 20(1):121. PubMed ID: 35317796
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
